NASDAQ:FLXN - Flexion Therapeutics Stock Price, Forecast & News

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics Inc (NASDAQ:FLXN) released its quarterly earnings data on Thursday, November, 7th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.01) by $0.01. The specialty pharmaceutical company had revenue of $21.79 million for the quarter, compared to analyst estimates of $18.85 million. Flexion Therapeutics had a negative net margin of 266.51% and a negative return on equity of 271.22%. View Flexion Therapeutics' Earnings History.

Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Flexion Therapeutics.

Flexion Therapeutics issued an update on its fourth quarter 2019 After-Hours earnings guidance on Thursday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $23.7-23.7 million, compared to the consensus revenue estimate of $24.15 million.

9 Wall Street analysts have issued 1 year target prices for Flexion Therapeutics' shares. Their forecasts range from $18.00 to $36.00. On average, they anticipate Flexion Therapeutics' stock price to reach $25.88 in the next twelve months. This suggests a possible upside of 40.5% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.

Headlines about FLXN stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Flexion Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Flexion Therapeutics.

Flexion Therapeutics saw a increase in short interest in December. As of December 13th, there was short interest totalling 7,450,000 shares, an increase of 6.9% from the November 28th total of 6,970,000 shares. Based on an average daily trading volume, of 660,100 shares, the days-to-cover ratio is presently 11.3 days. Approximately 23.4% of the company's stock are short sold. View Flexion Therapeutics' Current Options Chain.

Some companies that are related to Flexion Therapeutics include Karuna Therapeutics (KRTX), Uniqure (QURE), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), Epizyme (EPZM), Zogenix (ZGNX), ArQule (ARQL), Arena Pharmaceuticals (ARNA), Ra Pharmaceuticals (RARX), Synthorx (THOR), Aimmune Therapeutics (AIMT), Turning Point Therapeutics (TPTX), Aurinia Pharmaceuticals (AUPH), Xencor (XNCR) and Prestige Consumer Healthcare (PBH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Synergy Pharmaceuticals (SGYP), Aduro BioTech (ADRO), Cara Therapeutics (CARA), Verastem (VSTM), TherapeuticsMD (TXMD), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Omeros (OMER) and Celgene (CELG).

Flexion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (1.54%), Campbell Capital Management Inc. (0.04%) and Janney Montgomery Scott LLC (0.03%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Michael D Clayman, Neil Bodick and Samuel D Colella. View Institutional Ownership Trends for Flexion Therapeutics.

FLXN stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Campbell Capital Management Inc.. View Insider Buying and Selling for Flexion Therapeutics.

FLXN stock was acquired by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Michael D Clayman and Samuel D Colella. View Insider Buying and Selling for Flexion Therapeutics.

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FLXN stock can currently be purchased for approximately $18.41.

Flexion Therapeutics has a market capitalization of $702.80 million and generates $22.52 million in revenue each year. The specialty pharmaceutical company earns $-169,660,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. Flexion Therapeutics employs 272 workers across the globe.View Additional Information About Flexion Therapeutics.

The official website for Flexion Therapeutics is http://www.flexiontherapeutics.com/.

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]